Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug CounterfeitsGBI Research
June 25, 2012
60 Pages - SKU: XGBR3944320
Additional InformationPharma Supply Chains under the Microscope: Raising Revenue and Cutting out Counterfeiters.
The pharmaceutical companies are paying more attention than ever before to their supply chains as they attempt to boost profits and clamp down on fake drugs, states a new report by healthcare industry analysts GBI Research.
The report* examines the growing importance of strategic supply chain management in maximising revenue for global pharmaceutical companies, and how this is prompting the revision of traditional business models.
International pharmaceutical corporations are starting to tailor supply chains to products based on market demand and production costs. While manufacturing is commonly out-sourced to emerging economies where labor expenses are less substantial, branded products are produced closer to customer bases in developed countries as profit margins are higher and transportation costs lower.
These companies are also employing third-party logistics firms to improve flexibility in times of fluctuating demand. When drug requirements drop, pharmaceutical firms can simply reduce the order volume, rather than rendering costly in-house facilities inoperative.
GBI Research’s latest report also explains how developments in transportation methods are combating counterfeit drugs in the pharmaceutical industry – primarily through the implementation of Radio-Frequency Identification (RFID).
In the US, product callbacks have increased steadily over the last decade, with the Food and Drug Administration (FDA) recalling 1,742 drugs in 2009 alone. This occurs for a number of reasons including poor quality packaging, defective labelling and contamination.
As RFID devices are embedded in product packs and scanned by special readers, they eliminate human error as well as the need to replace labelling damaged in transit. But perhaps the most prominent quality of this technology is the capacity to store comprehensive and encrypted data, therefore reducing the possibility of fake medications entering the supply chain.
Traditionally, counterfeit drugs are manufactured in huge quantities and enter the system with bogus batch numbers and product codes that are identical to legitimate originals. Once in the supply chain these fakes are very difficult to recall, resulting in unnecessary expense for the firm and damaging public opinion. RFID is an important weapon in tackling this problem.
* Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
This report analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US.
This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
More Regulation & Policy reports by GBI Research
Taiwan Pharmaceutical Market Outlook 2013 by GBI Research
Taiwan Pharmaceutical Market Outlook 2013SummaryGBI Research, the leading business intelligence provider, has released its latest research Taiwan Pharmaceutical Market Outlook 2013. The report focuses on ...
South Korea Pharmaceutical Market Outlook 2013 by GBI Research
South Korea Pharmaceutical Market Outlook 2013SummaryGBI Research’s new report “South Korea Pharmaceutical Market Outlook 2013” provides in-depth analysis of the trends, issues and challenges facing ...
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players by GBI Research
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players Summary ...
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players by GBI ResearchSee all reports like this >>
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational PlayersSummaryGBI Research, ...
More United States Regulation & Policy reports
Contract Research Organizations in the US - Industry Market Research Report by IBISWorld
Contract Research OrganizationsThe industry experienced aggressive growth during the past five years as operators have worked to provide clients with a full-service experience, from product ...
Early Toxicology: Markets and Approaches by Kalorama Information
Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the ...
Freedonia Focus on Healthcare Overview: United States by Freedonia Focus Reports
This report discusses US healthcare for the years 2006 and 2011, with forecasts for 2016. Topics covered include market size, expenditure and medical provider segmentation, ...
How Have Zyprexa’s Patent Expiry, the Launch of Novel Atypical Antipsychotics, and Payer Decisions Reshaped U.S. Physician Behaviors in the Major Psychiatry Markets? by Decision ResourcesSee all reports like this >>
This U.S. Physician and Payer Forum explores payer and physician dynamics that affect prescribing practices for atypical antipsychotics for schizophrenia, bipolar disorder, ...
More United States reports
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Information Technology
- General Pharmaceuticals
- Manufacturing, Packaging & Detailing
- Pharmacy & Distribution
- Regulation & Policy
Regulation & Policy Reports